Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.81 |
| ▸ | CA9 | Q16790 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | AGER | Q15109 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031174 | 0.91 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL6828479 | 0.91 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL6302212 | 0.91 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL6828487 | 0.91 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL17174235 | 0.91 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL24125059 | 0.91 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL3822617 | 0.90 | CA12 (1.00) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL11910521 | 0.90 | CA12 (0.86) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL6534913 | 0.88 | MAPT (0.77) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL5044724 | 0.87 | MAPT (0.76) | MAPTMCOLN3CA12CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546309-B1 | ANTHRAPYRIDONE SULPHONIC ACID COMPOUNDS, PREPARATION AND USE THEREOF | UNIV DALIAN TECH (CN) | 2016-06-01 | — | — | EP | disclosed |
| EP-2546309-A1 | ANTHRAPYRIDONE SULPHONIC ACID COMPOUNDS, PREPARATION AND USE THEREOF | Dalian University Of Technology (CN) | 2013-01-16 | — | — | EP | disclosed |
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | AR, HTR3D, NR5A1 | MAPT 4558/4885MCOLN3 3755/4885CA12 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.